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Purpose: Transforming growth factor-β2 (TGF-β2) is associated with glaucomatous neuropathy, primarily via the
increased synthesis and secretion of extracellular matrix (ECM) proteins and remodeling of the optic nerve head (ONH).
Here, we investigated the signaling pathways used by TGF-β2 to stimulate ECM expression by ONH astrocytes and lamina
cribrosa (LC) cells.
Methods: TGF-β2 localization and secretion was examined in human donor tissues and ONH astrocytes and LC cells.
To examine TGF-β2 signaling, ONH astrocytes and LC cells were treated with recombinant TGF-β2, and phosphorylation
of Smad and non-Smad signaling proteins were examined by western blot analyses and immunostaining.
Results: TGF-β2 is significantly increased in the LC region of the ONH in glaucomatous eyes compared to age-matched
normal eyes (n=4, p<0.0013). ONH astrocytes and LC cells secrete TGF-β2, indicating that these cells may be an in vivo
source of TGF-β2 in the human ONH. In addition, treatment of ONH astrocytes and LC cells with exogenous TGF-β2
increased  ECM  protein  synthesis  and  secretion.  With  respect  to  TGF-β2  signaling,  recombinant  TGF-β2  induced
phosphorylation of canonical signaling proteins Smad2/3 but did not alter phosphorylation of non-canonical signaling
proteins extracellular signal-regulated kinases (ERK)1/2, p38, and c-Jun N-terminal kinases (JNK)1/2 proteins in ONH
astrocytes and LC cells. Exogenous TGF-β2 increased co-localization of pSmad2/3 with Co-Smad4 in the nucleus of ONH
astrocytes and LC cells further indicating activation of the canonical Smad signaling pathway. Furthermore, inhibition of
TGF-β I receptor activity by SB431542 or inhibition of Smad3 phosphorylation by SIS3 blocked TGF-β2 stimulated ECM
expression as well as activation of downstream canonical pathway signaling molecules. Knockdown of either Smad2 or
Smad3 via small interfering RNA (siRNA) reduced TGF-β2 stimulated ECM proteins in ONH astrocytes and LC cells.
Conclusions: These studies indicate that TGF-β2 utilizes the canonical Smad signaling pathway to stimulate ECM
synthesis in human ONH cells. Our studies also indicate that pSmad2/3 is required for TGF-β2 stimulation of ECM
remodeling.
Primary open angle glaucoma (POAG) is a progressive
optic neuropathy, characterized by the irreversible loss of
retinal ganglion cell (RGC) axons [1]. The pathogenic factors
responsible for POAG are still unknown. However, elevated
intraocular pressure (IOP) is a major causative and treatable
risk factor [2,3]. Chronic elevation of IOP induces optic nerve
head (ONH) changes [4,5], including compression of retinal
ganglion cell axons at the level of the lamina cribrosa (LC),
blockage of axoplasmic flow, and inhibition of retrograde
neurotrophin transport to RGC [6-8]. The glaucomatous ONH
shows characteristic cupping and excavation of the optic disc,
collapse and remodeling of the LC, and activation of ONH
astrocytes [4,9,10].
The LC region of the ONH consists of a characteristic
sieve-like structure through which RGC axons exit the eye
[7,11].  These  laminar  plates  contain  extracellular  matrix
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proteins such as elastin and collagens (I, III, V, and VI) [12].
Correct organization and assembly of the collagen and elastin
fibers in the LC provides both a supportive framework and
elasticity to the ONH, which is believed to protect RGC axons
from mechanical stress [13,14]. Major cell types present in the
human ONH include ONH astrocytes and LC cells [15,16].
These  cells  support  RGC  axons  by  synthesizing  growth
factors (e.g., neurotrophins) and extracellular matrix (ECM)
proteins [16-19].
Remodeling of the ECM, including changes in fibrillar
collagens,  basement  membrane  components,  and  elastin
composition,  is  characteristic  of  the  glaucomatous  ONH
[20-23].  The  extracellular  matrix  (ECM)  changes  include
backward  bowing  of  the  laminar  plates  with  increased
amounts of collagen I, IV, and VI. Altered elastin deposition
in LC is thought to alter the elastic properties of the ONH
[24]. Increased synthesis and deposition of ECM proteins in
the LC region may disrupt nutritional and mechanical support
to RGC axons, resulting in RGC atrophy. Several studies
suggest that ONH astrocytes and LC cells respond to elevated
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synthesis  in  the  LC  region  [25-27],  which  in  turn  causes
altered ECM protein expression.
TGF-β2 belongs to the TGF-β superfamily and plays a
fundamental role in the biology of the ECM [28]. In fibrotic
diseases,  elevated  TGF-β2  levels  lead  to  the  pathological
deposition of ECM proteins [29,30]. TGF-β2 appears to be
involved  in  the  pathogenesis  of  POAG.  Patients  with
glaucoma  have  higher  levels  of  TGF-β2  in  their  aqueous
humor [31], and TGF-β2 has been shown to increase ECM
protein in human trabecular meshwork (TM) cells [32-34]. In
addition, TGF-β2 increased IOP in cultured human perfused-
anterior eye segments [32,35]. Furthermore, adenoviral gene
transfer of active TGF-β2 elevates IOP in mice and rats and
reduces outflow facility in mice [36]. Robertson et al. [37] also
reported  that  gene  transfer  of  TGF-β1  into  the  anterior
chamber of rats elevated IOP.
A similar pathophysiology is observed in glaucomatous
ONH including elevated TGF-β2 and increased deposition of
ECM proteins. In the glaucomatous ONH, elevated TGF-β2
is  associated  with  ECM  remodeling  [38].  Fuchshofer  and
colleagues demonstrated that TGF-β2 treatment of cultured
ONH astrocytes upregulates mRNA and protein expression of
collagen I, collagen IV, fibronectin, connective tissues growth
factor  (CTGF),  tissue  transglutaminase  (TGM2),  and
thrombospondin-1 (TSP-1) [17]. These observations suggest
that TGF-β2 could be an initiation factor in ECM remodeling
in the glaucomatous ONH.
TGF-β2  signaling  involves  ligand  binding  to  TGF-β
receptors and activation of the canonical downstream Smad
signaling pathway or non-Smad signaling pathways [39,40].
TGF-β2  dimers  bind  to  the  type  II  receptor,  which
transphosphorylates the type I receptor. In the canonical Smad
signaling  pathway,  the  activated  type  I  receptor  then
phosphorylates  Smads  (Smad2/3),  which  triggers
heterodimerization with Co-Smad4 and translocation of the
complex to the nucleus to activate specific gene targets. In
non-Smad  signaling  pathways,  activated  TGF-β  receptors
utilize  extracellular  signal-regulated  kinases  (ERK),  P38
mitogen-activated  protein  kinases  (p38MAPK),  or  c-Jun  N-
terminal kinases (JNK) signaling proteins to activate gene
targets [41]. Although TGF-β may utilize ERK, p38MAPK, or
JNK signaling pathways in various cell types, Smad 2 and
Smad3 are thought to be primary TGF-β2-driven fibrogenesis
signals in many cell types, including mesangial cells, retinal
pigment epithelial cells, and skin fibroblasts [29,42].
Little  is  known  about  the  underlying  signaling
mechanisms responsible for TGF-β2 mediated synthesis and
deposition of ECM proteins in the normal or glaucomatous
ONH. We have previously reported that bone morphogenetic
protein-4 (BMP-4) and Smad signaling proteins are present in
human ONH tissues, isolated ONH astrocytes, and LC cells
and that exogenous BMP-4 treatment of isolated ONH cells
resulted  in  activation  of  the  canonical  signaling  pathway
[18]. However it is not clear if the TGF-β2 canonical Smad
signaling pathway or non-Smad signaling pathways are used
to  regulate  ECM  protein  synthesis  and  secretion  in  ONH
astrocytes and/or LC cells. In this study, we examined TGF-
β2 stimulation of ECM synthesis and deposition in isolated
human ONH astrocytes and LC cells to determine whether
canonical or non-canonical signaling pathways are used.
MATERIALS
Optic nerve head dissection and cell culture: Human ONH
astrocytes and LC cells were generated from dissected ONHs
and  characterized  according  to  previous  reports  [16,43].
Briefly, human donor eyes from regional eye banks were
obtained within 24 h of death, and the LC region of the ONH
was  dissected  from  the  remaining  ocular  tissue.  The  LC
tissues were cut into three to four explants and placed in
culture  plates  containing  Dulbecco’s  modified  Eagle’s
medium  (DMEM,  HyClone  Laboratories,  Logan,  UT)
containing  L-glutamine  (0.292  mg/ml,  Gibco  BRL  Life
Technologies, Grand Island, NY), penicillin (100 units/ml,)/
streptomycin (0.1 mg/ml, Gibco BRL Life Technologies),
amphotericin B (4 μg/ml; Gibco BRL Life Technologies), and
10% fetal bovine serum (Gibco BRL Life Technologies).
Treatment of ONH astrocytes and lamina cribrosa cells: ONH
astrocytes  and  LC  cells  were  grown  in  12  well  plates.
Confluent cells were washed twice with a sterile phosphate
buffer solution (PBS), and were kept in serum-free DMEM
for 24 h. A fresh serum-free medium with recombinant TGF-
β2 was added to ONH astrocytes and LC cells. For the TGF-
β2 dose–response study, ONH astrocytes and LC cells were
incubated with various concentrations of TGF-β2 (1.25, 2.5,
5, 10, and 20 ng/ml) for 24 h. ONH astrocytes and LC cells
grown in the serum-free medium for 24 h were considered to
be the control for the above experiment. Cell lysates and the
culture  medium  were  collected  and  analyzed  for  ECM
proteins.
For phosphorylation studies of Smads, ERK1/2, p38, or
JNK1/2, confluent ONH astrocytes and LC cells were washed
twice with PBS and kept in a serum-free medium for 24 h. A
fresh serum-free medium was then added and the cells were
incubated with recombinant TGF-β2 (5 ng/ml) for 30 min, 60
min,  or  120  min.  Cell  lysates  were  collected  and
immunoblotting with phospho-specific antibodies was used
to analyze the various signaling pathways.
To examine the effect of inhibiting the type I TGF-β
receptor (Alk5) or inhibiting Smad3 phosphorylation, the cells
were pre-incubated with SB431542 (10 uM, Pro. #S4317;
Sigma-Aldrich, St. Louis, MO) or SIS3 (25 um and 50 uM;
EMD Chemicals, Inc., San Diego, CA), respectively, for 1 h
before treatment. The ONH astrocytes and LC cells were
incubated  with  recombinant  TGF-β2  for  24  h,  with  and
without  SB431542  or  SIS3,  and  cell  lysates  and  the
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proteins.
To examine the effect of SB431542 or SIS3 on Smad and
non-Smad signaling pathways, ONH astrocytes and LC cells
were pre-incubated with SB431542 or SIS3 for 1 h and were
then treated with TGF-β2 for 1 h. Cell lysates were then
subjected to an analysis of the phosphorylation of Smad and
non-Smad signaling molecules by western immunoblotting.
Immunohistochemistry: Four sets of age-matched normal (76,
79, 84, and 97 years of age) and glaucomatous (72, 78, 82, and
99 years of age) human eyes were obtained from regional eye
banks within 6 h of death and were fixed in 10% formalin.
Fixed tissues were dehydrated, embedded in paraffin, and 8
um  sections  were  obtained.  Sections  were  deparaffinized,
rehydrated, and placed in 0.1% triton, followed by 20 mM
glycine for 15 min each. Sections were blocked in 10% normal
serum.  Slides  were  incubated  overnight  with  a  primary
antibody (Table 1) diluted 1:100 in 1.5% (v/v) normal serum,
were washed three times with PBS and this was followed by
a  2  h  incubation  in  appropriate  Alexa  Fluor™  secondary
antibodies  (1:200;  Invitrogen  Corporation,  Carlsbad,  CA).
Sections were subsequently incubated with DAPI for 30 min
to stain the nuclei, and were then washed and mounted. Images
were captured using a Zeiss 410 confocal imaging system
(Carl Zeiss, Thornwood, NY).
For orientation purposes, low power (10×) magnification
images were taken, which demonstrated ONH, retina, LC, and
blood vessels. For detailed study of TGF-β2 staining in the
LC, higher power magnification images were taken within the
LC region (white box in Figure 1). The relative intensity of
TGF-β2 staining was analyzed using ImageJ software (NIH)
with the RBG split option, thereby deconvoluting the green,
red, and blue channels. Subsequently, the red channel (for
TGF-β2) was selected and the relative intensity was measured.
The area for each image was kept constant since the entire red
channel was selected. A statistical analysis of the staining
intensity was performed with an unpaired Student’s  t-test
using GraphPadPrism 5 (La Jolla, CA).
Co-localization of pSmad3 and Smad4: Lamina cribrosa cells
were grown on glass coverslips. Confluent cells were kept in
a  serum-free  medium  for  24  h  and  were  incubated  with
recombinant TGF-β2 (5 ng/ml) in a serum-free medium for
60 min. The cells were then fixed with 3.5% formaldehyde (in
PBS) for 10 min. The coverslips were washed with PBS and
treated with 0.02% triton for 10 min. The coverslips were
washed twice with PBS and blocked with 10% normal donkey
serum for 1 h. The coverslips were then incubated overnight
with  primary  antibodies  for  pSmad3  or  pSmad2  and  Co-
Smad4 (Table 1), were washed 4 times with PBS, and were
incubated with secondary antibodies for 2 h. The specimens
were then incubated with DAPI for 30 min to stain the nuclei,
and were subsequently washed and mounted. Images were
captured using a Zeiss 410 confocal imaging system (Carl
Zeiss).
Protein extraction and western blot analysis:
Cell lysate—Total cellular protein was extracted from
cultured ONH astrocytes and LC cells using a Mammalian
Protein Extraction Buffer (#78501; Pierce Biotech, Rockford,
TABLE 1. LIST OF ANTIBODIES
Antibody (cat #), dilutions, source
Fibronectin (sc-18827), 1:1000, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
PAI-1 (sc-5297), 1:1000, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
TGF-β2 (sc-90), 1:500, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
Collagen I (sc-8783), 1:500, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
Collagen VI (AB-7821), 1:2000, Millipore Corporate, Billerica, MA
Elastin (MAB-2503), 1:1000, Millipore Corporate, Billerica, MA
β-actin (MAB-1501), 1:2000, Millipore Corporate, Billerica, MA
Goat Anti Mouse, 1:20000, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
Goat Anti Rabbit, 1: 20000, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
pSmad3 (#9520), 1:500, Cell Signaling Technology. Inc. Danvers, MA
Smad3 (#9513), 1:500, Cell Signaling Technology. Inc. Danvers, MA
Pp38MAPK (#9215), 1:500, Cell Signaling Technology. Inc. Danvers, MA
P38MAPK (#9212), 1:500, Cell Signaling Technology. Inc. Danvers, MA
pJNK1/2 (#4668), 1:500, Cell Signaling Technology. Inc. Danvers, MA
JNK1/2 (#9252), 1:500, Cell Signaling Technology. Inc. Danvers, MA
pERK1/2 (sc-81492), 1:500, Santa Cruz Biotechnology, Inc. Santa Cruz, CA.
ERK1/2 (#4695), 1:500, Cell Signaling Technology. Inc. Danvers, MA
pSmad2 (#3104), 1:500, Cell Signaling Technology. Inc. Danvers, MA
Smad2 (#3122), 1:500, Cell Signaling Technology. Inc. Danvers, MA
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Biotech). Protein concentration was determined using the Bio-
Rad  Dc  protein  assay  system  (Bio-Rad  Laboratories,
Richmond,  CA).  Cellular  proteins  were  separated  on
denaturing polyacrylamide gels and then transferred to PVDF
membranes  by  electrophoresis.  Blots  were  blocked  with
SuperBlock Blocking Buffer (Prod# 37537; Pierce Biotech)
for 1 h. The blots were then incubated overnight with specific
primary antibodies (Table 1). The membranes were washed
with  Tris-buffered  saline/Tween  buffer  (TBST)  and  were
incubated  with  a  corresponding  horseradish  peroxidase-
conjugated secondary antibody (Table 1). The proteins were
then  visualized  in  a  Fluor  ChemTM  8900  imager  (Alpha
Innotech Corporation, San Leandro, CA) using ECL detection
reagents  (SuperSignal  West  Femto  Maximum  Sensitivity
Substrate; Pierce Biotechnology). To ensure equal protein
loading, the same blot was subsequently incubated with a β-
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Figure 1. Immunohistochemical evaluation of transforming growth factor (TGF)-β2 expression in normal and glaucomatous optic nerve head
(ONH) tissues. A representative immunostaining for TGF-β2 expression in age-matched normal (97 years) and glaucomatous (99 years)
human ONH tissues. A: ONH tissue section from a normal human donor stained for TGF-β2 (red), glial fibrillary acidic protein (GFAP;
green), and 4',6-diamidino-2-phenylindole (DAPI; blue) at lower magnification, and C: showing part of the lamina cribrosa (LC) in the white
box, at higher magnification. B: ONH tissue section from glaucomatous human eyes stained for TGF-β2 (red), GFAP (green), and DAPI
(blue) at lower magnification, and D: showing LC in the white box, at higher magnification. E: Control (no primary antibody for TGF-β2 and
GFAP) merged with DAPI in normal ONH, and F: in glaucomatous ONH. G: Relative intensity measurements of TGF-β2 staining in the LC
region in four age-matched normal and glaucomatous ONH tissues, showing significant higher staining for TGF-β2 in glaucomatous ONH
tissues compared to normal human ONH tissues [student’s t-test, p<0.0013; ** versus normal human ONH tissues; n=4].actin monoclonal antibody and the blot was developed using
a horseradish peroxidase-conjugated secondary antibody.
Conditioned  medium—To  detect  secreted  TGF-β2
proteins  in  the  conditioned  medium,  confluent  ONH
astrocytes and LC cells were grown in a serum-free medium
for 24 h. The culture medium was then concentrated 20 times
and equal volumes of the conditioned medium were analyzed
via western immunoblotting, as described above.
ELISA  immunoassay  for  fibronectin:  The  conditioned
mediums obtained from three ONH astrocytes cell lines and
three LC cell lines were centrifuged at 2000 rpm to remove
cellular debris. A total 50 ul of the conditioned medium was
diluted to 150 ul with a dilution buffer, and soluble fibronectin
was quantified using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (cat # ECM 300; Chemicon
International,  Temecula,  CA).  The  amounts  of  soluble
fibronectin  (ug/ml)  were  plotted  for  each  treatment  using
GraphPadPrism 5.
Small interfering RNA and transfection: Small interfering
RNA (siRNA) for Smad3 and non-targeting siRNA controls
were purchased from Dharmacon (SMARTpool, La Jolla,
CA). Transfection of siRNA was performed as described in
the manufacturer’s guidelines. Briefly, ONH astrocytes and
LC cells were plated in 12-well plates containing DMEM with
10%  fetal  bovine  serum.  At  30%–40%  confluence,
transfection of siRNA was performed. In one tube, 4 ul of
DharmaFECT  1  Transfection  Reagent  (T-2001–01;
Dharmacon, Lafayette, CO) was mixed gently with 196 μl of
Opti-MEM medium (Invitrogen Corporation, Carlsbad, CA)
and was incubated for 5 min at room temperature. In separate
tubes, various concentrations of siRNAs were mixed gently
with 196 μl of Opti-MEM medium. These two tubes were
combined, gently mixed, and incubated for 20 min at room
temperature. After incubation, Opti-MEM medium was added
to obtain a final volume of 2 ml for each well (25 nM and 50
nM of Smad3 siRNA, 100 nM for Smad2 siRNA and 100 nM
of non-targeting siRNA controls). Cells were twice washed
with sterile PBS and were incubated with siRNA transfection
solution for 48 h at 37 °C. Subsequently, cells were washed
with serum-free DMEM medium and were treated with TGF-
β2 (5 ng/ml) in serum-free DMEM medium for 24 h. The
culture medium and cell lysates were analyzed for RSmad2/3,
fibronectin, and plasminogen activator inhibitor (PAI)-1.
RESULTS
Increased TGF-β2 expression in glaucomatous human ONH
tissues: To confirm that TGF-β2 expression is increased in the
human  glaucomatous  ONH,  we  first  examined  four  age-
matched normal and glaucomatous ONH tissues. Figure 1A,C
demonstrate TGF-β2 immunostaining (red) merged with glial
fibrillary acidic protein (GFAP; green) in a representative
ONH region of a normal human donor (97 years). Figure 1B,D
represent TGF-β2 immunostaining merged with GFAP in a
representative glaucomatous ONH sample (99 years). TGF-
β2 was localized in the pre-lamina and LC region along axon
bundles,  and  was  also  associated  with  blood  vessels.
Significantly, TGF-β2 and GFAP staining was higher in the
glaucomatous ONH tissues. In addition, there was increased
co-localization of TGF-β2 with GFAP in the glaucomatous
ONH tissues compared to normal ONH tissues. No staining
was observed in negative controls that included normal IgG
(not  shown)  or  omission  of  the  primary  antibody  (Figure
1E,F). The relative intensity of TGF-β2 was measured by
ImageJ software (NIH) and indicated that TGF-β2 protein
levels  were  increased  significantly  in  the  age-matched
glaucomatous  ONH  tissues  compared  to  the  controls
(p<0.0013; **verses normal human ONH tissues; n=4; Figure
1G).
Presence of TGF-β2 in ONH cells: To examine the role of
elevated TGF-β2 in ECM modulation in the ONH, we next
sought to determine whether ONH astrocytes and LC cells
secrete endogenous TGF-β2. Confluent ONH astrocytes and
LC  cells  were  kept  in  serum-free  medium  for  24  h.  The
conditioned  medium  (concentrated  20×)  was  subjected  to
western blot analysis of TGF-β2. ONH astrocytes and LC cells
secreted  endogenous  TGF-β2  (Figure  2).  In  addition,
endogenous TGF-β2 was present in lysates obtained from
human  ONH  tissues  (data  not  shown),  confirming  our
immunohistochemical results in Figure 1. Recombinant TGF-
β2 was used as a positive control for the western blots (data
not shown), and this standard, as well as the samples from
ONH astrocytes and LC cells, had similarly sized 25 kDa
bands (Figure 2). These results confirm that ONH astrocytes
and LC cells secrete TGF-β2.
Recombinant TGF-β2 increases synthesis and deposition of
ECM proteins in ONH astrocytes and LC cells: To delineate
the effect of exogenous TGF-β2 on ECM proteins in vitro, we
sought  to  determine  whether  the  addition  of  human
recombinant TGF-β2 stimulates ECM expression in ONH
astrocytes and LC cells. We performed dose response curves
for  the  effects  of  TGF-β2  on  fibronectin  and  PAI-1
production. Optic nerve head astrocytes (n=3) and LC cells
(n=3)  were  treated  with  various  concentrations  of
recombinant TGF-β2 (1.25, 2.5, 5, 10, and 20 ng/ml) for 48
h. The effect of TGF-β2 on secreted fibronectin (FN) was
examined by ELISA immunoassay (ONH astrocytes - Figure
3A, and LC cells - Figure 3B), and western blot analysis was
used to examine cellular FN and PAI-1 (Figure 3C). In the
ELISA immunoassay, recombinant TGF-β2 increased soluble
FN in a dose dependant manner in both cell types (Figure
3A,B). Recombinant TGF-β2 (5 ng/ml) increased soluble FN
levels twofold compared to the vehicle controls. The response
of TGF-β2 treatment on FN and PAI-1 protein was measured
by  western  blot  analysis  (cell  lysates)  and  by  ELISA
(secretion). The secretion of fibronectin appeared to be dose
dependent up to the highest TGF-β2 concentration tested (20
ng/ml). However, the induction of FN and PAI-1 in the cell
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induction at 10 ng/ml. This apparent reduction in the TGF-
β2 response may be due to enhanced secretion of FN from the
cell at the higher dose, which would correlate with the increase
in  FN  secretion  seen  in  the  ELISA  results.  Since  a
concentration of 5 ng/ml significantly increased soluble FN,
we elected to utilize this concentration for subsequent studies.
Recombinant TGF-β2 activates the canonical Smad signaling
pathway in ONH astrocytes and LC cells: To understand the
signaling  pathways  used  by  TGF-β2  to  stimulate  ECM
proteins, we sought to study whether recombinant TGF-β2
activated  Smad  and/or  non-Smad  signaling  pathways  in
isolated ONH astrocytes and LC cells. Since the canonical
TGF-β signaling pathway involves activation of Smads via
phosphorylation  of  Smad2  and/or  Smad3,  we  sought  to
determine  whether  TGF-β2  phosphorylates  Smad2/3  in
isolated ONH astrocytes and LC cells. ONH astrocytes and
LC cells were incubated with TGF-β2 (5 ng/ml) for 0, 15, 30,
60, and 120 min, and phosphorylation of Smad2 and Smad3
was  examined  by  western  immunoblotting.  Recombinant
TGF-β2 increased the phosphorylation of Smad2 and Smad3
in ONH astrocytes in a time dependent manner, and increased
Smad3 phosphorylation in LC cells compared to baseline
controls. It appears that TGF-β2 also phosphorylates higher
molecular  bands  for  pSmad2  and  pSmad3,  which  are
recognized by respective antibodies. Total Smad2, Smad3,
Figure  2.  Western  blot  analysis  of
transforming  growth  factor  (TGF)-β2
protein in optic nerve head (ONH) cells.
ONH  astrocytes  and  lamina  cribrosa
(LC)  cells  were  grown  in  serum-free
medium for 24 h. Culture medium (20X
concentrated) was subjected to western
blot analysis for TGF-β2 expression. A
positive band for TGF-β2 at 25 kDa was
detected in western blots, indicating that
ONH  astrocytes  and  LC  cells  secrete
TGF-β2.
Figure  3.  Effect  of  recombinant
transforming  growth  factor  (TGF)-β2
on extracellular matrix (ECM) protein
synthesis and deposition in optic nerve
head  (ONH)  astrocytes  and  lamina
cribrosa  (LC)  cells.  Three  different
ONH  astrocytes  cell  lines  and  four
different LC cell lines were treated with
various concentrations of recombinant
TGF-β2 (0, 2.5, 5, 10, and 20 ng/ml) for
24  h,  and  culture  medium  and  cell
lysates were subjected to an analysis of
ECM proteins. A: The effect of TGF-β2
on FN secretion in ONH astrocytes, and
B:  LC  cells,  was  examined  using
enzyme-linked  immunosorbent  assay
(ELISA).  Statistical  analysis  was
performed  in  Graph  Pad  Prism  using
one-way  ANOVA  (n=3  *,  p<0.0001
versus control). Recombinant TGF-β2
increased soluble fibronectin (FN) in a
dose dependant fashion. C: Cell lysates
obtained from LC cells were subjected
to western blot analysis of cellular FN
and  plasminogen  activator  inhibitor
(PAI)-1 in LC cells. Recombinant TGF-
β2 increased synthesis of cellular FN
and PAI-1 in a dose dependant manner.
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(Figure 4A). These findings suggest that recombinant TGF-
β2 can activate Smad2/3 in ONH astrocytes and LC cells.
Next, we sought to study whether TGF-β2 also activates
non-Smad  signaling  pathways  such  as  ERK1/2,  p38,  or
JNK1/2 in ONH astrocytes and LC cells. We examined the
phosphorylation of these signal kinases using immunoblotting
with  phospho-specific  antibodies  (Figure  4B).  In  ONH
astrocytes and LC cells, recombinant TGF-β2 did not alter the
phosphorylation of ERK1/2 compared to the baseline control
at 15, 30, 60, or 120 min. Similarly, recombinant TGF-β2 did
not alter phosphorylation of p38 or JNK1/2 in ONH astrocytes
or LC cells. Detection of equal amounts of actin as well as
total ERK1/2, p38 or JNK1/2 ensured equal loading of total
proteins. Thus, TGF-β2-induced ECM protein expression did
not  appear  to  utilize  downstream  signaling  activation  of
ERK1/2, p38, or JNK1/2 in ONH astrocytes and LC cells.
TGF-β2 increases co-localization of phosphorylated Smad3
and co-Smad4 in LC cells: To further study the canonical
Smad  signaling  pathway  in  LC  cells,  we  performed  co-
localization of pSmads with Co-Smad4. Activated receptor
Smads  form  a  complex  with  Co-Smad4,  which  facilitates
nuclear import and interaction with the target genes. Since our
previous experiments demonstrated that recombinant TGF-
β2 phosphorylated Smad2/3, we sought to examine whether
TGF-β2 increases the co-localization of pSmad 2 or pSmad3
with  Co-Smad4  in  LC  cells  (Figure  5).  Even  in  serum
deprived, untreated LC cells, there was some co-localization
of  pSmad3  with  Co-Smad4  in  the  nucleus  (Figure  5A),
indicating the presence of an endogenous autocrine TGF-β
signaling  pathway  via  Smad3.  In  contrast,  there  is  no
detectable level of immunostaining for pSmad2 in untreated
LC cells (Figure 5C). However, in TGF-β2 stimulated LC
cells, the co-localization of phosphorylated Smad3 and Co-
Smad4  was  increased  in  both  the  cytoplasm  and  nucleus
(Figure 5B). In addition, p-Smad2 and Co-Smad4 levels were
increased  and  these  factors  were  co-localized  in  TGF-β2
stimulated LC cells (Figure 5D). Similar findings were found
in  the  ONH  astrocytes  (data  not  shown).  These  findings
support our previous immunoblotting results indicating that
TGF-β2  activates  Smads  phosphorylation,  which  then
translocates the Smad2/3/4 complex to the nucleus.
Inhibition of the type I TGF-β receptor activity or inhibition
of Smad3 phosphorylation blocks TGF-β2 stimulation of ECM
proteins:  We  next  sought  to  examine  whether  TGF-β2
induced Smad signaling is required for ECM stimulation in
Figure 4. Effect of transforming growth factor (TGF)-β2 on activation of Smad2/3 in optic nerve head (ONH) astrocytes and lamina cribrosa
(LC) cells. ONH astrocytes and LC cells were incubated with recombinant TGF-β2 (5 ng/ml) for 0, 15, 30, 60, and 120 min. A: Cell lysates
were analyzed for phosphorylated Smad3, total Smad3, phosphorylated Smad2, Smad2, and actin. B: ONH astrocytes and LC cells were
treated with or without TGF-β2 for 30 min, 60 min, and 120 min, and total cell lysates were also examined for phosphorylated extracellular
signal-regulated kinases (ERK)1/2, total ERK1/2, phosphorylated p38, total p38, phosphorylated c-Jun N-terminal kinases (JNK)1/2, total
JNK1/2, and actin. Recombinant TGF-β2 increased phosphorylation of Smad3 and Smad2 in ONH astrocytes as well as Smad3 phosphorylation
in LC cells at 15 min, 30 min, 60 min and 120 min but did not alter phosphorylation ERK, p38, and JNK1/2 in ONH astrocytes and LC cells.
These signaling proteins were detected at expected molecular sizes.
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1751Figure 5. Effect of recombinant transforming growth factor (TGF)-β2 on localization of Smad2/3 with Co-Smad4 in lamina cribrosa (LC)
cells. LC cells were incubated with recombinant TGF-β2 (5 ng/ml) for 60 min. Cells were then fixed with 3.5% formaldehyde solution and
were stained with antibodies for pSmad3, pSmad2, and Smad4. A: Co-localization of pSmad3 (red) and Smad4 (green) in untreated LC cells,
and B: in TGF-β2 treated cells. C: Co-localization of pSmad2 (red) and Smad4 (green) in untreated LC cells, and D: in TGF-β2 treated cells.
E: Negative controls consisted of LC cells incubated with rabbit and mouse IgG and were co-stained with nuclear stain DAPI (blue).
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1752ONH  astrocytes  and  LC  cells.  In  the  canonical  TGF-β2
signaling pathway, secreted TGF-β2 binds to the type II TGF-
β receptor, which then activates the type I TGF-β receptor.
Activation of type I TGF-β receptor leads to phosphorylation
of  downstream  signaling  Smads  or  non-Smad  signaling
mediators [40]. We examined the effect of the type I TGF-β
receptor inhibitor SB431542, a selective and potent inhibitor
of  activity  of  the  TGF-β1  activin  receptor-like  kinases
(ALK5). The addition of SB431542 (10 μM) blocked TGF-
β2 stimulation of cellular FN in ONH astrocytes and LC cells
(Figure 6A). These findings demonstrate that TGF-β2-driven
stimulation of ECM proteins requires active TGF-β RI in
ONH astrocytes and LC cells.
To elucidate whether TGF-β2-driven stimulation of ECM
proteins is mediated via activation of Smad3, we inhibited
Smad3  phosphorylation  with  SIS3,  a  specific  inhibitor  of
Smad3. ONH astrocytes and LC cells were pre-incubated with
SIS3 (25 uM and 50 uM) 1 h before treatment with TGF-β2.
We observed that TGF-β2 stimulation of FN secretion in ONH
astrocytes and LC cells was reduced to a baseline control by
SIS3 treatment (Figure 6B). This finding suggests that TGF-
β2-driven stimulation of ECM proteins requires activation of
Smad3.
Effect of SB431542 and SIS3 on TGF-β2-Stimulated Smad
Signaling:  Next,  we  examined  whether  the  effects  of  the
TGFβR1 (SB431542) or Smad 3 (SIS3) inhibitors on TGF-
β2 stimulated ECM were mediated via inhibition of TGF-β2
induced signaling. We pre-incubated ONH astrocytes and LC
cells with either SB431542 or SIS3 for 1 h and then treated
them with TGF-β2 for 1 h. Total cell lysates were subjected
to an analysis of phosphorylation of Smad and non-Smad
signaling  molecules.  TGF-β2  alone  caused  increased
phosphorylation of Smad2 and Smad3 after 1 h of treatment
(Figure  7A).  The  addition  of  SB431542  blocked
phosphorylation of Smad2 and Smad3, indicating inhibition
of  the  downstream  signaling  pathway  through  TGF-βR-I.
Total protein levels of Smad2 and Smad3 did not change with
TGF-β2 treatment alone or with the combination of TGF-β2
and SB431542, compared to the vehicle control (Figure 7A).
In addition, TGF-β2 alone or TGF-β2 and SB431542 did not
alter phosphorylation of ERK1/2, p38 or JNK1/2 (Figure 7B),
further supporting our previous findings that TGF-β2 does not
activate non-Smad signaling pathways in ONH astrocytes or
LC  cells.  SIS3  selectively  inhibited  TGF-β2  induced
phosphorylation of Smad3 without affecting total Smad3, and
SIS3 did not inhibit phosphorylation of Smad2 levels in ONH
astrocytes and LC cells (Figure 7A). Moreover, SIS3 did not
affect phosphorylation of non-Smad signaling molecules such
as ERK1/2, p38, or JNK1/2 (Figure 7B).
siRNA knockdown of Smad3 or Smad2 blocks TGF-β2-driven
stimulation of FN and PAI-1 in ONH astrocytes and LC Cells:
Our  previous  pharmacological  experiments  suggested  that
Smad3 is required for TGF-β2 stimulation of ECM proteins.
In  addition  to  Smad3,  TGF-β2  also  activated  Smad2
phosphorylation in ONH astrocytes and LC cells (Figure 4 and
Figure 5), indicating the potential role of Smad2 in TGF-β2
Figure  6.  Effect  of  inhibition  of
transforming  growth  factor  (TGF)-β
receptor I or Smad3 phosphorylation on
TGF-β2-driven  extracellular  matrix
(ECM)  stimulation.  Optic  nerve  head
(ONH) astrocytes and lamina cribrosa
(LC)  cells  were  pre-incubated  with  a
type  I  TGF-β  receptor  inhibitor
(SB431542, 10 uM) or an inhibitor of
Smad3 phosphorylation (SIS3, 25 and
50  uM),  1  h  before  treatment  with
recombinant TGF-β2 (5 ng/ml) for 24 h.
A:  Total  cell  lysates,  and  B:  the
conditioned medium were subjected to
western blot analysis of fibronectin. A:
The  effect  of  SB431542  on  TGF-β2
stimulated cellular fibronectin (FN) was
assessed  by  western  blot  in  ONH
astrocytes  and  LC  cells.  B:  Effect  of
inhibition of phosphorylation of Smad3
on  TGF-β2  stimulated  ECM  was
examined by western blot analysis of
secreted FN in ONH astrocytes and LC
cells.  Inhibition  of  Smad3
phosphorylation  reduced  TGF-β2
stimulated  FN  secretion  in  ONH
astrocytes and LC cells.
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1753signaling  in  ONH  astrocytes  and  LC  cells.  To  examine
whether Smad2 or Smad3 are preferentially used by TGF-β2
to induce ECM stimulation, we conducted siRNA knockdown
of Smad3 (Figure 8A-D) and Smad2 (Figure 8E-H) along with
control  siRNAs  (RISC-Free  siRNAs  and  non-targeting
siRNAs). The cells were treated with siRNAs for 48 h and
were then treated with TGF-β2 for 24 h. Fibronectin, PAI-1,
Smad3, Smad2, and actin protein levels were assessed by
western immunoblotting and were measured by densitometric
analysis. Transfection with Smad3-siRNA (25 nM and 50 nM)
resulted in a significant (p<0.001) reduction of Smad3 protein
levels compared to control siRNAs (50 nM; Figure 8A,B).
Control siRNAs did not significantly alter Smad3 protein
levels compared to the vehicle control, indicating sequence-
specific silencing of our target siRNAs. Next, ONH astrocytes
and LC cells were treated with TGF-β2 with and without
siRNAs for Smad3. Western blot and densitometric analysis
demonstrated that reduction of Smad3 via siRNA (25 nM and
50 nM) significantly blocked the stimulatory effects of TGF-
β2 on FN and PAI-1 proteins (Figure 8A,C,D). These results
indicate that Smad3 is required for TGF-β2 stimulation of
ECM proteins in ONH astrocytes and LC cells.
Next, we examined whether TGF-β2 requires Smad2 to
induce ECM stimulation in ONH astrocytes and LC cells.
Fibronectin,  PAI-1,  Smad2,  and  actin  protein  levels  were
assessed by western blot (Figure 8E) and were measured by
densitometric  analysis  (Figure  8F-H).  Transfection  with
Smad2  siRNA  (100  nM)  resulted  in  significant  (n=3,
*p<0.0018 verses control) reduction of Smad2 protein levels
compared to control siRNAs (100nM) in ONH astrocytes and
LC cells (Figure 8E,F). Control siRNAs did not significantly
alter Smad2 protein levels compared to the vehicle control,
indicating sequence-specific silencing of our target siRNAs.
Western blot and densitometric analysis demonstrated that
reduction  of  Smad2  via  siRNA  significantly  blocked  the
stimulatory  effects  of  TGF-β2  on  FN  and  PAI-1  proteins
(Figure 8E,F-H). These results indicate that both Smad3 and
Smad2 are downstream signaling proteins used for TGF-β2
stimulation of ECM proteins in ONH astrocytes and LC cells.
DISCUSSION
In glaucoma, the LC region of the ONH is the primary site of
injury that leads to the death of RGC axons [44]. The LC is
the  weakest  part  of  the  ocular  globe  and  is  thus  more
vulnerable to elevated IOP. Chronic IOP elevation is thought
to cause cupping and excavation of the optic disc, collapse and
remodeling of the LC, and activation of ONH astrocytes [4,
10,45]. Alteration in the synthesis, deposition, and quality of
Figure 7. Effect of inhibition of transforming growth factor (TGF)-β receptor I or Smad3 phosphorylation on Smad and non-Smad signaling
pathways. Optic nerve head (ONH) astrocytes and lamina cribrosa (LC) cells were pre-incubated with SB431542 (10 uM) or SIS3 (25 uM),
1h before treatment with TGF-β2. ONH astrocytes and LC cells were then treated with recombinant TGF-β2 for 1 h and total cell lysates were
subjected to western blot analysis for phosphorylation of Smad and non-Smad signaling pathways. A: western blot analysis of pSmad3, Smad3,
pSmad2, and Smad2 in ONH astrocytes and LC cells. B: western blot analysis of phosphorylated extracellular signal-regulated kinases
(ERK)1/2, total ERK1/2, phosphorylated p38, total p38, phosphorylated c-Jun N-terminal kinases (JNK)1/2, and total JNK1/2 in ONH
astrocytes and LC cells. Samples were run in the same gel but not in the order presented. SB431542 inhibited TGF-β2 induced phosphorylation
of Smad2/3, whereas SIS3 selectively inhibited phosphorylation of Smad3. The inhibitors had no effect on members of the non-Smad pathway.
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1754ECM proteins in the LC region has been associated with
glaucomatous ONH changes and is thought to be detrimental
to RGC axons. For example, remodeling of the ECM in the
glaucomatous ONH may contribute to the backward bowing
of  the  laminar  plates  and  compression  of  RGC  axons.
Remodeling  of  the  ECM  includes  changes  in  fibrillar
collagens, basement membrane components, and degradation
of elastin fibers [21]. Extracellular matrix changes previously
reported  in  the  glaucomatous  ONH  include  (a)  increased
amounts of collagens I, IV, and VI [21], and (b) elastin fiber
degradation [20]. Thus, the alteration of ECM proteins in the
LC region may disrupt nutritional and mechanical support to
RGC axons, resulting in RGC atrophy.
Transforming  growth  factor-β2  is  a  known  fibrotic
modulator.  Pena  and  colleagues  reported  increased
immunohistochemical  expression  of  TGF-β2  in  the
glaucomatous  ONH  [38].  Our  results  are  the  first  to
independently verify this observation. However, Pena et al.,
(1999)  did  not  elucidate  the  cellular  source  of  TGF-β2
expression pattern in the glaucomatous ONH. There are at
Figure 8. Effect of Smad2 or Smad3 siRNA on transforming growth factor (TGF)-β2 stimulation of fibronectin (FN) and plasminogen activator
inhibitor (PAI)-1 in optic nerve head (ONH) astrocytes and lamina cribrosa (LC) cells. A: ONH astrocytes and LC cells were treated with
small interfering RNA (siRNA) controls (lane 1=Non-targeting siRNA; lane 2=RISC-Free siRNA) or with Smad3 siRNA (25 nM and 50 nM;
lanes 4–5) for 48 h, and were then treated with recombinant TGF-β2 (5 ng/ml) for 24 h. Cellular FN, PAI-1, total Smad3, and actin were
assessed by western blot. B: Relative densities of Smad3 and actin in ONH astrocytes were measured using densitometric analysis of the
western blots. Smad3 was normalized to actin and the fold change in Smad3 over the vehicle control was plotted (n=3,* p<0.001 versus
control). C and D: Relative FN or PAI-1 was normalized to actin and the fold change in FN (C) or PAI-1(D) over the vehicle control was
plotted (n=3,* p<0.001 verses TGF-β2 treated). E: ONH astrocytes and LC cells were treated with siRNA controls (lane 1=Non-targeting
siRNA; lane 2=RISC-Free siRNA) or with Smad2 siRNA (lanes 4–5, 100 nM in duplicate) for 48 h, and were then treated with recombinant
TGF-β2 (5 ng/ml) for 24 h. F: Cellular FN, PAI-1, total Smad2, and actin were assessed by western blot. Smad2 levels in ONH astrocytes
were normalized to actin and the fold change in Smad2 over the vehicle control was plotted (n=3, *p<0.0018 verses control). G and H: Relative
densities of FN, PAI-1, and actin were measured using densitometric analysis. Relative densities of FN or PAI-1 were normalized to actin
and the fold change in FN (G) or PAI-1(H) over vehicle the control was plotted (n=3, p<0.0048 for FN and p<0.0015 for PAI-1, * verses
TGF-β2 treated).
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1755least five different cell types reported to be present within the
human  ONH,  including  astrocytes,  LC  cells,  microglia,
endothelial cells, and pericytes [9,15,46,47]. Many studies
assume that ONH astrocytes and LC cells respond to elevated
IOP by increasing TGF-β2 synthesis and secretion, which in
turn causes alteration of ECM protein expression. However,
definitive studies verifying this assumption were lacking.
Consistent with the Pena study, we observed that TGF-
β2 is elevated in the glaucomatous ONH. Interestingly, TGF-
β2  was  significantly  increased  in  the  LC  region  of  the
glaucomatous ONH, and TGF-β2 co-localized with GFAP
positive cells, indicating that ONH astrocytes may be a major
source of TGF-β2 in vivo. We also have demonstrated that
treatment  of  ONH  astrocytes  and  LC  cells  with  TGF-β2
increased ECM protein synthesis in both ONH astrocytes and
LC cells, suggesting that both ONH astrocytes and LC are
capable of responding to TGF-β2 in vivo. This is the first
report to illustrate how human LC cells respond to TGF-β2
with increased ECM protein synthesis and secretion.
TGF-β2  may  alter  ECM  metabolism  via  several
mechanisms. Treatment of ONH astrocytes and LC cells with
recombinant TGF-β2 increased soluble FN and PAI-1 in a
dose  dependant  manner.  PAI-1  is  involved  in  fibrosis  by
regulating the activity of matrix metalloproteases (MMPs),
and matrix metalloproteases have been shown to be involved
in  ECM  remodeling  of  the  glaucomatous  ONH  [48,49].
Neumann  et  al.  demonstrated  that  recombinant  TGF-β2
increases  MMP-2  and  PAI-1  in  ONH  astrocytes  [50].
Increased type I and VI collagen and elastin are thought to
alter  the  mechanical  and  elastic  properties  of  LC  in
glaucomatous ONH. Fuchshofer and colleagues [17] showed
that  TGF-β2  increases  FN,  collagen  I  and  IV,  tissue
transglutaminase, and CTGF in ONH astrocytes. Results from
the  present  study  confirm  the  findings  of  these  previous
studies,  showing  that  recombinant  TGF-β2  increases  FN,
PAI-1,  elastin,  and  collagen  I  and  collagen  VI  in  ONH
astrocytes.  However,  in  addition  to  ONH  astrocytes,  our
current  study  demonstrated  that  LC  cells  also  respond  to
recombinant TGF-β2 by increasing FN, PAI-1, elastin, and
collagen I, and VI. Since LC cells secrete TGF-β2 and respond
to recombinant TGF-β2 via increasing ECM proteins, it is
possible that LC cells may also play an important role in
altering the mechanical and elastic properties of LC. These
observations reinforce the hypothesis that TGF-β2 is involved
in ECM changes in the glaucomatous ONH.
The signaling pathway used by TGF-β2 to increase ECM
expression in human ONH astrocytes and LC cells has not
been  previously  identified.  In  many  cell  types,  TGF-β2
induced  fibrosis  utilizes  the  canonical  Smad  pathway  via
Smad2 and Smad3 [51]. Importantly, in some cell types, non-
Smad pathways, including ERK, p38MAPK, and JNK, have
also been reported to be activated by TGF-β2 [40]. Thus,
determining which pathway(s) ONH astrocytes and LC cells
utilize to regulate ECM protein synthesis and secretion is of
great  importance  with  respect  to  the  pathophysiology  of
glaucoma.
Our  results  demonstrated  the  presence  of  TGF-β2,
endogenous  pSmad2/3  and  their  co-localization  with  Co-
Smad4, thus indicating that ONH astrocytes and LC cells
possess  autocrine  TGF-β2  mediated  Smad  signaling.  In
addition,  treatment  with  exogenous  TGF-β2,  increased
pSmad2 and pSmad3 levels and their co-localization with Co-
Smad4 in the nucleus, indicating that isolated ONH astrocytes
and  LC  cells  can  also  respond  to  exogenous  TGF-β2  via
activation of canonical Smad signaling. Interestingly, TGF-
β2 did not activate phosphorylation of non-Smad signaling
pathways such as ERK1/2, p38, or JNK1/2 in either ONH
astrocytes or LC cells. Therefore, TGF-β2 does not appear to
stimulate non-Smad pathways in ONH astrocytes and LC
cells.
We  next  determined  if  the  canonical  Smad  signaling
pathway  was  required  for  TGF-β2-driven  ECM  protein
regulation. Pre-incubation with SB431542 or SIS3 reversed
TGF-β2  stimulated  FN  and  PAI-1  expression  to  vehicle
control levels. SB431532 is a potent and selective inhibitor of
TGF-ßRI activity. SB431542 has been reported to inhibit pro-
fibrotic actions of TGF-β2 in skin fibroblasts and hepatic cells.
SB431542  inhibited  TGF-β2  induced  phosphorylation  of
Smad2 and Smad3 without altering total Smad2 or Smad3
protein levels. Furthermore, the Smad3 inhibitor SIS3 [52]
reduced TGF-β2 regulated phosphorylation of Smad3 but not
Smad2. As expected, neither SB431542 nor SIS3 had an effect
on the non-Smad signaling pathways assessed by examining
the phosphorylation of ERK1/2, p38, and JNK1/2.
We  further  examined  the  effect  Smad2  and  Smad3
knockdown on TGF-β2 stimulated ECM protein expression
in ONH astrocytes and LC cells. siRNA knockdown of Smad2
and Smad3 reduced the total amount of Smad2 and Smad3 in
ONH  astrocytes  and  LC  cells.  Knockdown  of  Smad2  or
Smad3 inhibited TGF-β2 stimulation of FN and PAI-1 in
ONH astrocytes and LC cells. Therefore, Smad2 as well as
Smad3 is used for TGF-β2 stimulated ECM proteins. Since
knockdown of either Smad2 or Smad3 completely reversed
TGF-β2  stimulated  ECM  proteins  to  control  levels,  both
signaling molecules may be required for TGF-β2 stimulation
of ECM proteins.
Conclusions: The present study provides both in vivo and
in vitro evidence to support the conclusion that TGF-β2 is
involved in ECM remodeling by cells of the human ONH. In
addition, TGF-β2-driven ECM stimulation requires activation
of the canonical Smad signaling pathway via Smad2/3. Non-
Smad signaling pathways do not appear to be involved in
TGF-β2 stimulation of ECM protein synthesis and secretion
by ONH astrocytes or LC cells. Inhibition of the type I TGF-
β receptor or knockdown of either Smad2 or Smad3 reversed
TGF-β2 stimulated ECM proteins in ONH astrocytes and LC
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1756cells. Therefore, inhibition of these downstream signals may
provide a therapeutic target to prevent ECM remodeling in the
glaucomatous ONH.
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